Patents by Inventor NgocDiep LE

NgocDiep LE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for Treating EGFR Mutant Cancers
    Publication number: 20210100812
    Abstract: Methods for the treatment of EGFR mutated cancer. For example, treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations (e.g., L858R and ex19del), the acquired or resistant “gatekeeper” T790M mutation, or any combination of these mutations.
    Type: Application
    Filed: December 1, 2020
    Publication date: April 8, 2021
    Inventors: NgocDiep LE, Gerald LELAIS, Yong JIA
  • Methods for treating EGFR mutant cancers
    Patent number: 10881664
    Abstract: Methods for the treatment of EGFR mutated cancer. For example, treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations (e.g., L858R and ex19del) the acquired or resistant “gatekeeper” T790M mutation, or any combination of these mutations.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: January 5, 2021
    Assignee: NOVARTIS AG
    Inventors: NgocDiep Le, Gerald Lelais, Yong Jia
  • METHODS FOR TREATING EGFR MUTANT CANCERS
    Publication number: 20180117059
    Abstract: Methods for the treatment of EGFR mutated cancer. For example, treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations (e.g., L858R and ex19del) the acquired or resistant “gatekeeper” T790M mutation, or any combination of these mutations.
    Type: Application
    Filed: May 12, 2016
    Publication date: May 3, 2018
    Inventors: NgocDiep LE, Gerald LELAIS, Yong JIA